Literature DB >> 11147812

IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1.

C Miranda1, A Greco, C Miele, M A Pierotti, E Van Obberghen.   

Abstract

TRK-T1 oncogene is generated by the rearrangement of the NGF receptor TrkA with TPR. This gives rise to the constitutive tyrosine autophosphorylation and activation of the kinase. To study TRK-T1 oncogenic signaling and compare it to that induced by the genuine receptor TrkA, we investigated the involvement of IRS-1, a docking protein implicated in mitogenic signaling induced by several growth factors, in TRK-T1 and TrkA signaling. Here, we show that IRS-1 and IRS-2 are phosphorylated on tyrosine in presence of both TRK-T1 and the activated TrkA receptor. These tyrosine phosphorylations lead to IRS-1- and IRS-2-induced recruitment of p85PI3K, SHP-2, and Grb2 and increase in PI 3-kinase activity associated with IRS-1. Furthermore, we found that TRK-T1 is able to activate c-fos serum responsive element in cooperation with IRS-1 and IRS-2. We observed that TRK-T1 stimulates DNA synthesis in wild-type fibroblasts but not in IRS-1(-/-) mouse embryo fibroblasts. Yeast two-hybrid system experiments showed the occurrence of direct interaction between TRK and IRS molecules, which suggests involvement of different modes of interactions. On the whole, our results suggest that IRS-1 and IRS-2 could be substrates of TRK-T1 and TrkA, and hence could participate in their signal generation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11147812     DOI: 10.1002/1097-4652(200101)186:1<35::AID-JCP1003>3.0.CO;2-X

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  13 in total

Review 1.  Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.

Authors:  Mian Liu; Pei Chen; Hui-Yu Hu; Deng-Jie Ou-Yang; Rooh-Afza Khushbu; Hai-Long Tan; Peng Huang; Shi Chang
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

Review 2.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

3.  Nerve growth factor receptor TrkA, a new receptor in insulin signaling pathway in PC12 cells.

Authors:  Thangiah Geetha; Shraddha D Rege; Salome E Mathews; Susan O Meakin; Morris F White; Jeganathan Ramesh Babu
Journal:  J Biol Chem       Date:  2013-06-07       Impact factor: 5.157

4.  Role of STAT3 in in vitro transformation triggered by TRK oncogenes.

Authors:  Claudia Miranda; Tiziana Fumagalli; Maria Chiara Anania; Maria Grazia Vizioli; Sonia Pagliardini; Marco A Pierotti; Angela Greco
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 5.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

6.  Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.

Authors:  Josenilson C Oliveira; Kellen K Souza; Marília M Dias; Marcel C Faria; Eduardo R Ropelle; Marcelo B S Flores; Mirian Ueno; Lício A Velloso; Sara T Saad; Mario J A Saad; José B C Carvalheira
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-09       Impact factor: 4.553

7.  Downstream of tyrosine kinase/docking protein 6, as a novel substrate of tropomyosin-related kinase C receptor, is involved in neurotrophin 3-mediated neurite outgrowth in mouse cortex neurons.

Authors:  Wei qi Li; Lei Shi; Yuan gang You; Yan hua Gong; Bin Yin; Jian gang Yuan; Xiao zhong Peng
Journal:  BMC Biol       Date:  2010-06-18       Impact factor: 7.431

Review 8.  The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins.

Authors:  Fumihiko Hakuno; Toshiaki Fukushima; Yosuke Yoneyama; Hiroyasu Kamei; Atsufumi Ozoe; Hidehito Yoshihara; Daisuke Yamanaka; Takashi Shibano; Meri Sone-Yonezawa; Bu-Chin Yu; Kazuhiro Chida; Shin-Ichiro Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-26       Impact factor: 5.555

9.  NGF signaling in PC12 cells: the cooperation of p75(NTR) with TrkA is needed for the activation of both mTORC2 and the PI3K signalling cascade.

Authors:  Sara Negrini; Rosalba D'Alessandro; Jacopo Meldolesi
Journal:  Biol Open       Date:  2013-07-12       Impact factor: 2.422

10.  Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc.

Authors:  E Roccato; C Miranda; V Ranzi; M Gishizki; M A Pierotti; A Greco
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.